Navigation Links
Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
Date:3/18/2013

MENLO PARK, California and BALLERUP, Denmark, March 18, 2013 /PRNewswire/ --

Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now initiated a Phase 1 clinical trial of VBY-891 - a selective cathepsin S inhibitor.

     (Logo: http://photos.prnewswire.com/prnh/20130221/595427)

The first Phase 1 trial of VBY-891 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of VBY-891 in healthy adults.

"The initiation of this Phase 1 trial represents a significant development objective for Virobay's collaboration with LEO Pharma," stated Robert Booth , Ph.D., Chief Executive Officer of Virobay. "Virobay has plans to initiate clinical studies with additional cathepsin inhibitors during 2013 as we seek to develop new therapies for underserved diseases. Published prelinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with dermatological disorders such as psoriasis. In addition, our own preclinical data with selective cathepsin S inhibitors has demonstrated efficacy in models of both psoriasis and atopic dermatitis," stated Robert Booth . "We look forward to assessing the data from these Phase 1 trials, which will incorporate the evaluation of several biomarkers, to guide our Phase 2 clinical development plans for VBY-891."

"Reaching this important milestone in our collaboration with Virobay brings us one step closer to provide an oral treatment for psoriasis patients. We believe that VBY-891 has the potential to provide an oral treatment that may alleviate symptoms of psoriasis. LEO Pharma strives to constantly ex
'/>"/>

SOURCE Virobay, Inc. and LEO Pharma A/S
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Educating, Informing, and Successfully Preparing the Marketplace for New Bio-Pharma Products
2. Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
3. Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-SMN Rx Data Presented at 2013 AAN Annual Meeting
4. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
5. Sagent Pharmaceuticals Selects ProspectoRx and Clinical Pharmacology
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
7. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
8. Salix Pharmaceuticals Commits $1.125M to AGA Research Foundation
9. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
10. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
11. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 ... healthcare funding changes brought about by the ... both reimbursement and prescribing of pharmaceutical therapies. ... (MCOs) cover beneficiaries through new regulations and ... is occurring in the health exchanges—state-based marketplaces ...
(Date:7/31/2014)... 2014 Hovione today announced that its ... successfully passed a pre-approval inspection by the US Food and ... the FDA Consumer Safety Officer, Ms. Britanny Terhar , ... July and concluded on the 25 th . The ... and guidelines of Good Manufacturing Practices (GMP) and no Form ...
(Date:7/31/2014)... announces the list of stocks featured in the Analyst Blog. ... news and events impacting stocks and the financial markets. Stocks ... - Free Report ), Gilead (Nasdaq: GILD - Free ... ), AbbVie (NYSE: ABBV - Free Report ) and ... Today, Zacks is promoting its ,Buy, stock recommendations. Get ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... N.J. , Aug. 4 ... Co., Ltd, (collectively, "Daiichi Sankyo") have reached an agreement ... settle their patent litigation involving Apotex,s challenge to Daiichi ... "the ,821 patent") covering Evoxac® (cevimeline HCl).  Under the ...
... Cardica, Inc. (Nasdaq: CRDC ) today announced that it will release ... Tuesday, August 17, 2010 , after the markets close. Cardica,s management will host a conference ... update on the company,s business. , , , ... , , , ...
Cached Medicine Technology:Daiichi Sankyo Settled Patent Litigation for Evoxac® 2Cardica to Announce Fiscal 2010 Fourth Quarter and Year End Financial Results on Tuesday, August 17, 2010 2
(Date:7/31/2014)... To further educate the public, The Rothenberg ... safety information regarding leaving children in hot vehicles: , ... consequences. Because a child’s body can heat up three ... children alone in a hot vehicle puts them at ... Statistics of Children Left Alone in a Car , ...
(Date:7/31/2014)... Texas (PRWEB) July 31, 2014 ... Austin-based physicians Tracey Haas and Tim Gueramy, announced the ... Docbook Enterprise. , According to Dr. Tim Gueramy, CEO ... their solution because physician leaders from each one had ... saw a huge benefit for their respective organizations to ...
(Date:7/31/2014)... Johns Hopkins have developed blood and saliva tests that ... a substantial number of patients. The tests screen for ... cancer cells lingering in the mouth or other parts ... published in the July 31 issue of JAMA ... is a window of opportunity in the year after ...
(Date:7/31/2014)... Rich Dad® Education , a leader in financial ... for Humanity. The yard sale was a success. In just ... proceeds donated to Habitat for Humanity of Lee and Hendry ... were donated to the Habitat for Humanity ReStore thrift store ... , Of the over $650, roughly $30 was raised ...
(Date:7/31/2014)... -- With the World Health Organization reporting that the ... risen to 729, the U.S. Centers for Disease ... for,the region. The "Level 3 travel advisory" urges ... Guinea, Liberia and Sierra Leone -- be avoided. ... West Africa," CDC Director Dr. Tom Frieden told reporters ...
Breaking Medicine News(10 mins):Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 3Health News:Physician Demand for Integrated Communication Platform Drives DocbookMD Growth 2Health News:Blood and saliva tests help predict return of HPV-linked oral cancers 2Health News:Rich Dad Education Charity Yard Sale to Benefit Habitat for Humanity of Lee and Hendry Counties a Success 2Health News:CDC Issues Travel Warning as West Africa Ebola Outbreak Worsens 2
... July 14, 2009 Infectious disease specialists at UT Southwestern ... severe Staphylococcus aureus infections, providing crucial insight ... to this pathogen and opening new doors for improved therapeutic ... on understanding precisely what the bacterium S aureus does ...
... , DENVER, July 13 DaVita Inc. (NYSE: ... with chronic kidney disease (CKD), today announced Mahesh Krishnan, MD, MPH has ... July 13, 2009. , , (Logo: ... is recognized as a leader in clinical trials for drugs and devices. ...
... , DENVER, July 13 ... Luncheon will be held in Denver July 23 at the ... luncheon, sponsored by MillerCoors, will honor and welcome Her Excellency, ... annual fundraising event raises awareness of global healthcare needs and ...
... , ... The Extraordinary Leader, performance thought leaders John Zenger and Joseph Folkman revealed the 16 ... first book,s publication, they have discovered, through an extensive study conducted over four years, that ... ...
... A new study of the cognitive processes involved with ... temptation than active resistance to temptation. Using ... given the chance to gain money dishonestly by lying ... activity when telling the truth, implying that extra cognitive ...
... , , , Gail ... Sector in Current Economic Climate , , ... Cross will be the featured speaker at a National Press Club Luncheon on Tuesday, ... through Turbulent Economic Times." , , (Logo: ...
Cached Medicine News:Health News:Researchers map how staph infections alter immune system 2Health News:Researchers map how staph infections alter immune system 3Health News:DaVita Clinical Research Appoints Mahesh Krishnan as Vice President 2Health News:DaVita Clinical Research Appoints Mahesh Krishnan as Vice President 3Health News:Project C.U.R.E. and MillerCoors to Welcome the First Lady of Ghana to Colorado for First Ladies' Luncheon in Denver 2Health News:Project C.U.R.E. and MillerCoors to Welcome the First Lady of Ghana to Colorado for First Ladies' Luncheon in Denver 3Health News:Project C.U.R.E. and MillerCoors to Welcome the First Lady of Ghana to Colorado for First Ladies' Luncheon in Denver 4Health News:Zenger Folkman Releases Latest Book: The Inspiring Leader: Unlocking the Secrets of How Extraordinary Leaders Motivate 2Health News:Zenger Folkman Releases Latest Book: The Inspiring Leader: Unlocking the Secrets of How Extraordinary Leaders Motivate 3Health News:Neuroimaging suggests that truthfulness requires no act of will for honest people 2Health News:Neuroimaging suggests that truthfulness requires no act of will for honest people 3Health News:American Red Cross President to Address National Press Club Luncheon 2
... the state of the art product for ... articular surfaces does not restrict natural movement, ... a wide area of contact between the ... of cement create a homogeneous cement mantle ...
... The TC-PLUS Solution tricompartmental total knee ... with knee arthroplasty. State-of-the-art design and manufacturing ... achieve optimum biomechanical function as well as ... polyethylene tibial insert to keep wear to ...
The RT-PLUS Solution is an axially supported rotation knee prosthesis for cemented implantation. The modern design allows extremely sparing resections. The components exhibit an anatomical geometry t...
... System is a long term, quality solution ... in both posterior stabilized and anatomically correct ... provides the flexibility needed to address patients' ... of identification keeps the user in mind ...
Medicine Products: